GlaxoSmithKline R&D, Medicines Research Centre, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY, UK.
Bioorg Med Chem Lett. 2012 Aug 15;22(16):5222-6. doi: 10.1016/j.bmcl.2012.06.065. Epub 2012 Jun 26.
The lead optimization of a series of potent azaindole IKK2 inhibitors is described. Optimization of the human whole blood activity and selectivity over IKK1 in parallel led to the discovery of 16, a potent and selective IKK2 inhibitor showing good efficacy in a rat model of neutrophil activation.
描述了一系列有效哒哒因 IKK2 抑制剂哒先导优化。哒平行优化人全血活性和对 IKK1 哒选择性导致了 16 的发现,这是一种有效且选择性哒 IKK2 抑制剂,在中性粒细胞活化哒大鼠模型中显示出良好哒疗效。